Aquestive Therapeutics (AQST) Net Income towards Common Stockholders (2017 - 2026)

Aquestive Therapeutics' Net Income towards Common Stockholders history runs 10 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 64.86% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$68.9 million, a 27.05% decrease from a year earlier, with the FY2025 full-year figure at -$83.8 million, down 89.83% from the prior year.
• Net Income towards Common Stockholders advanced to -$8.1 million in Q1 2026 per AQST's latest filing, from -$31.9 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $8.1 million in Q1 2023 and bottomed at -$31.9 million in Q4 2025.
• The 5-year median for Net Income towards Common Stockholders is -$12.5 million (2022), against an average of -$11.7 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 161.03% in 2023 and plunged 465.55% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$12.4 million in 2022, then jumped by 34.33% to -$8.1 million in 2023, then slumped by 110.27% to -$17.1 million in 2024, then sank by 86.81% to -$31.9 million in 2025, then surged by 74.71% to -$8.1 million in 2026.
• Per Business Quant, the three latest AQST Net Income towards Common Stockholders figures stand at -$8.1 million (Q1 2026), -$31.9 million (Q4 2025), and -$15.4 million (Q3 2025).